Soares Lismeia Raimundo, Menezes Gabriella Coelho, Barreto Ana Paula Menna, Sant'Anna Mônica de Souza Lima, Cardoso Nadir Machado Alves, Casseb Jorge Simão do Rosário, Fonseca Fernando Luiz Affonso
. Departamento de Nutrição, Programa de Nutrição Clínica, Professora na UFRJaneiro - Campus Macaé, Macaé, RJ, Brasil.
. Doutora na Linha de Pesquisa Clínica na FMABC, Santo André, SP, Brasil.
Rev Assoc Med Bras (1992). 2020 Feb 27;66(1):67-73. doi: 10.1590/1806-9282.66.1.67. eCollection 2020.
Individuals living with HIV seem to be more prone to changes in the redistribution of body fat, characterized as lipodystrophy, which may occur in conjunction with metabolic diseases. In the present study, such impacts were assessed in adults with and without HIV and associated with the time of virus diagnosis and treatment with antiretroviral.
A cross-sectional study with 123 adults, in which 87 had HIV and 36 without HIV, of both sexes, in outpatient follow-up at the Specialized Care Service (SAE) in Macaé-RJ. The following were made: 1) Alteration in body fat distribution, measured by anthropometric parameters and self-reported lipodystrophy; 2) Biochemical profile; 3) Association between HIV diagnosis time and antiretroviral treatment.
54.47% (n = 67) males, 45.52% (n = 56) females, mean age 37 years. Of these 87 were people living with HIV, 29% (n = 25) had self-reported lipodystrophy, mean time of virus infection, and antiretroviral treatment (5.80 ± 4.56 and 5.14 ± 3.82 years), respectively. Patients with self-reported lipodystrophy had a greater change in body fat distribution between 3-6 years of HIV diagnosis and a negative cholesterol profile. The antiretroviral treatment time influenced total cholesterol and triglycerides, even for patients without self-reported lipodystrophy, with a further nine years under treatment.
In this study, the negative cholesterol profile was mainly related to antiretroviral treatment time, even for patients without self-reported lipodystrophy, and changes in body fat distribution, measured by anthropometry, was especially associated with time for HIV infection in those with lipodystrophy self-reported.
感染艾滋病毒的个体似乎更容易出现身体脂肪重新分布的变化，即脂肪代谢障碍，这可能与代谢性疾病同时发生。在本研究中，对有和没有艾滋病毒的成年人进行了此类影响评估，并将其与病毒诊断时间和抗逆转录病毒治疗相关联。
一项针对123名成年人的横断面研究，其中87人感染艾滋病毒，36人未感染艾滋病毒，涵盖男女，均在里约热内卢州马卡埃市专科护理服务中心（SAE）进行门诊随访。进行了以下操作：1）通过人体测量参数和自我报告的脂肪代谢障碍来测量身体脂肪分布的变化；2）生化指标；3）艾滋病毒诊断时间与抗逆转录病毒治疗之间的关联。
男性占54.47%（n = 67），女性占45.52%（n = 56），平均年龄37岁。这87名是艾滋病毒感染者，其中29%（n = 25）自我报告有脂肪代谢障碍，病毒感染和抗逆转录病毒治疗的平均时间分别为（5.80 ± 4.56和5.14 ± 3.82年）。自我报告有脂肪代谢障碍的患者在艾滋病毒诊断3至6年期间身体脂肪分布变化更大，且胆固醇指标呈阴性。抗逆转录病毒治疗时间影响总胆固醇和甘油三酯水平，即使对于没有自我报告脂肪代谢障碍的患者也是如此，治疗时间延长九年情况更明显。
在本研究中，胆固醇指标呈阴性主要与抗逆转录病毒治疗时间有关，即使对于没有自我报告脂肪代谢障碍的患者也是如此；通过人体测量法测量的身体脂肪分布变化，在自我报告有脂肪代谢障碍的患者中尤其与艾滋病毒感染时间相关。
